Clinical trials on Glioblastoma

Glioblastoma: An Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), stands as one of the most aggressive and common forms of primary brain tumors in adults. This malignancy originates from the supportive tissue of the brain, known as glial cells, which provide nourishment, support, and protection for the brain’s nerve cells. Due to its highly invasive nature, glioblastoma poses significant challenges in treatment, often leading to a prognosis that is both daunting and grim.

The clinical presentation of glioblastoma can vary widely among patients but typically includes symptoms such as persistent headaches, seizures, nausea, and neurological deficits like weakness or speech difficulties. These symptoms arise as the tumor grows and exerts pressure on or invades surrounding brain tissue. Diagnosis of glioblastoma is primarily achieved through imaging techniques like Magnetic Resonance Imaging (MRI), with confirmation and further characterization through biopsy or surgical resection.

Treatment and Prognosis

Treatment for glioblastoma is multifaceted, aiming to prolong survival and improve the quality of life. The standard treatment protocol includes surgical resection to remove as much of the tumor as safely possible, followed by radiation therapy and chemotherapy with temozolomide. Despite these interventions, the prognosis for glioblastoma patients remains poor, with median survival times ranging from 12 to 18 months post-diagnosis. Research into novel therapies, including immunotherapy, targeted therapy, and tumor-treating fields (TTF), offers hope for future advancements in glioblastoma treatment.

Given its complexity and aggressiveness, glioblastoma underscores the need for ongoing research and innovation in neuro-oncology. The battle against this formidable foe is a testament to the resilience of patients, families, and the medical community striving for breakthroughs that will one day turn the tide in the fight against brain cancer.

Prognosis for Glioblastoma: Understanding the Outlook

Glioblastoma represents an aggressive type of brain cancer with complex treatment challenges. The prognosis for glioblastoma varies, with factors such as patient age, tumor location, and overall health influencing outcomes. Generally, the median survival time is approximately 12 to 18 months from diagnosis, but this can extend with optimal management. Long-term survival beyond two years is rare, with only about 5-10% of patients reaching this milestone. Advances in medical research are ongoing, aiming to improve the long-term prospects for those diagnosed with glioblastoma.

Complications in Glioblastoma

Glioblastoma, a type of brain cancer, can lead to various complications that affect health and quality of life. As the tumor grows, it may cause increased pressure inside the skull, resulting in headaches, nausea, and vomiting. Seizures might be experienced, which can be sudden and frightening. Changes in brain function can lead to difficulty with speech, memory, and concentration, making everyday tasks challenging. Muscle weakness or paralysis on one side of the body is also possible, impacting mobility and independence. Fatigue is common, often profound, reducing the capacity to engage in normal activities. As the disease progresses, personality changes or mood swings may occur, affecting social interactions and emotional well-being. These complications can significantly diminish quality of life, creating a need for support and assistance in daily living.

Innovative Treatment Methods for Glioblastoma

For the management of glioblastoma, several non-clinical trial options are recommended. Dietary adjustments, focusing on nutrient-rich foods, may support overall health. Physical activity, tailored to the ability of the patient, can enhance well-being. Pharmacotherapy, including medications prescribed by healthcare professionals, is utilized to manage symptoms and improve quality of life.

Modern technology also plays a role. Wearable devices are capable of monitoring health parameters, while mobile apps provide reminders for medication and appointments. Advanced software assists in tracking symptoms and progress, facilitating personalized care. These methods, combined with professional medical advice, contribute to a comprehensive approach to glioblastoma management.

  • CT-EU-00112349

    Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    • VAL-083
    • Troriluzole
    • VT1021
    • Paxalisib
    • Lomustine
    • Temozolomide
    • Regorafenib
  • Exploring New Treatments for Brain Tumors Targeting Cancer Stem Cells

    This clinical trial focuses on developing new treatments for brain tumors, specifically targeting a type of cell called cancer stem cells (CSCs) that play a crucial role in the aggressiveness and resistance to current treatments of these tumors. Brain tumors, such as Glioblastoma (GBM), are among the most aggressive and have a low survival rate, making the need for new therapeutic approaches urgent.

    The study is particularly interested in how a lipid called Sphingosine-1-phosphate (S1P) influences these cancer stem cells. S1P is involved in the tumor’s ability to grow, resist drugs, and spread, making it a potential target for new treatments. By understanding how the environment around the tumor affects these cells and their metabolism, especially under low oxygen conditions (hypoxia), researchers hope to find new ways to stop the tumor from growing and resisting treatment.

    The main goal of this project is to identify new molecular and metabolic targets that are crucial for the survival and resistance to chemotherapy of tumor stem cells. This could lead to the development of new drugs that can inhibit the proliferation of CSCs and, consequently, tumor progression.

    For patients participating in this study, researchers will be investigating specific markers related to the development and progression of brain tumors to improve diagnosis, treatment, and monitoring. This research could significantly improve the prognosis for patients suffering from brain tumors by identifying new therapeutic strategies and potential biomarkers.

  • A study to test the safety and impact of new drugs on advanced solid tumors

    This study is testing a new treatment called [177Lu]Lu-FF58 in patients with advanced or late-stage serious cancers. The aim of treatment is to target proteins in the body called integrins, which are mainly found in these cancers. The study is divided into two parts: “escalation” and “expansion”. The escalation section will test different doses of the new treatment to find the most appropriate dose. The “expansion” part will assess whether the treatment is safe and can help control the disease using the best dose found in the first part. During the study, researchers will perform regular tests to understand the effects of the treatment on the body and how effective the treatment is against the cancer.

    • 68Ga-FF58- new potential radiopharmaceutical agent designed for imaging cancerous tumors
    • 177Lu-FF58- new radiopharmaceutical for advanced tumors
  • Trying a new drug for glioblastoma cancer treatment

    This clinical trial is aimed at trying out a new treatment for a newly diagnosed brain tumor called Glioblastoma. There will be used a drug named 131I-TLX101, and the researchers are testing how safe it is and what dose can be used safely. The 131I-TLX101 drug is given through veins, and the amount of it that the researchers give will go up slowly to see what is the safest dose. It is important to keep a close eye on side effects and how they may affect patients.

    • 131I-TLX101
  • New method to boost drug’s efficacy against brain cancer

    This study is testing a special device called SonoCloud-9, which is used in combination with a common chemotherapy drug, carboplatin, in people with a specific type of brain cancer called glioblastoma multiforme that has relapsed. The brain has a type of wall, called the blood-brain barrier, which prevents many substances from entering the body, including chemotherapy drugs. The SonoCloud-9 device helps chemotherapy overcome this barrier using sound waves. Scientists hope this means that a larger dose of the drug will be able to fight brain cancer. This study will compare the results of this new approach with current standard treatments. Doctors will follow patients for up to 7 months and then visit them every 3 months until the study ends. They will measure the size of the tumor at the beginning and when they think it may grow again, and check survival rates at 12 and 18 months.

    • Lomustine
    • Temozolomide
    • Carboplatin
  • New treatment for glioblastoma using pazopanib and temozolomide

    This study examines a new treatment for glioblastoma multiforme, a type of brain cancer, using two drugs: pazopanib and temozolomide. Patients who have completed initial treatments like surgery and radio-chemotherapy are eligible. The study has two phases: first, determining the best dose of pazopanib, and second, assessing how this dose, combined with temozolomide, affects the progression of the cancer and the overall survival of patients.

    • Pazopanib
    • Temozolomide
  • Vaccine trial for brain cancer treatment

    This clinical trial is testing the CV09050101 mRNA vaccine (CVGBM) in adults with a specific type of brain cancer known as glioblastoma multiforme or astrocytoma. This study is divided into two parts and will mainly include patients who have just been diagnosed and have undergone surgery to remove a brain tumor. In the study, patients will be given the vaccine after surgery and treatment with radiation therapy (and possibly chemotherapy). This is actually a type of vaccine intended to fight cancer. The first part of the study is finding the right amount of CVGBM that can be given to people. The second part further investigates how well people perform with a selected amount of CVGBM. Patients will receive a total of 7 doses on specific days, approximately over a two-month period. They can then receive further doses for up to one year, depending on how well they feel and what their doctor and research team recommend.

    • CV09050101 mRNA vaccine
  • New treatment options for glioblastoma

    This clinical trial is exploring different treatments for patients with glioblastoma, a type of brain cancer. In the GBM AGILE trial, patients are being treated with a variety of medications, including temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. Additionally, there’s a biological treatment being tested, known as ADI-PEG 20, and patients may receive radiation therapy as part of their treatment regimen​. By using advanced methods to adapt treatment to each patient’s response, the study aims to extend survival and improve quality of life. It is open to many participants and will progress through two stages of treatment assessment, adapting as new data comes in. The goal is to personalize therapy, maximize effectiveness, and advance understanding of glioblastoma treatment.

    • Pegargiminase/ADI-PEG 20
    • Dianhydrogalactitol/VAL-083
    • Troriluzole
    • VT1021
    • Paxalisib
    • Lomustine
    • Temozolomide
    • Regorafenib